# Canagliflozin With Gemcitabine in Pancreatic Carcinoma

> **NCT05903703** · NA · NOT_YET_RECRUITING · sponsor: **Zhang Xiaofeng,MD** · enrollment: 20 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Canagliflozin and Gemcitabine
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT05903703
- **Lead sponsor:** Zhang Xiaofeng,MD
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-10-01
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-03-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-06-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05903703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05903703, "Canagliflozin With Gemcitabine in Pancreatic Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05903703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*